

INFORMATION DISCLOSURE CITATIONForm PTO-1449 (Modified)
(Use several sheets if necessary)ATTY. DOCKET NO.
AERX058CON3SERIAL NO.
To Be AssignedAPPLICANT
Gonda, et al.FILING DATE
HerewithGROUP
To Be Assigned**U.S. PATENT DOCUMENTS**

978 U.S. PTO
09/048773
05/03/01

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
A.J.L.	AA	3,812,854	05/1974	Michaels et al.	—	—	
	AB	3,991,304	11/1976	Hillsman	—	—	
	AC	4,106,503	08/1978	Rosenthal et al.	—	—	
	AD	4,361,401	11/1982	Smith et al.	—	—	
	AE	4,604,847	08/1986	Moulding, Jr. et al.	—	—	
	AF	4,627,432	12/1986	Newell et al.	—	—	
	AG	4,677,975	07/1987	Edgar et al.	—	—	
	AH	4,686,231	08/1987	Bender et al.	—	—	
	AI	4,796,614	01/1989	Nowacki et al.	—	—	
	AJ	4,819,629	04/1989	Jonson	—	—	
	AK	4,877,989	10/1989	Drews et al.	—	—	
	AL	4,907,581	03/1990	King	—	—	
	AM	4,926,852	05/1990	Zoltan et al.	—	—	
	AN	4,984,158	01/1991	Hillsman	—	—	
	AO	5,006,343	04/1991	Benson et al.	—	—	
	AP	5,011,678	04/1991	Wang et al.	—	—	
A.J.L.	AQ	5,167,506	12/1992	Kilis et al.	—	—	

EXAMINER

Aaron J. Law

DATE CONSIDERED

6/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)
(Use several sheets if necessary)

ATTY. DOCKET NO.
AERX058CON3

SERIAL NO.
To Be Assigned

APPLICANT
Gonda, et al.

FILING DATE
Herewith

GROUP
To Be Assigned

ALL	AR	5,284,133	02/1994	Burns et al.	—	—	
	AS	5,363,842	11/1994	Mishelevich et al.	—	—	
	AT	5,364,838	11/1994	Rubsamen	—	—	
	AU	5,394,866	03/1995	Riston et al.	—	—	
	AV	5,404,871	04/1995	Goodman et al.	—	—	
	AW	5,450,336	09/1995	Rubsamen et al.	—	—	
	AX	5,497,944	03/1996	Weston et al.	—	—	
	AY	5,743,250	04/1998	Gonda et al.	—	—	
ALL	AZ	5,941,240	08/1999	Gonda et al.	—	—	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
ALL	BA	0 186 280	10/1995	Europe	—	—		
	BB	0 232 235 A2	08/1987	Europe	—	—		
	BC	2 104 393	03/1983	United Kingdom	—	—		
	BD	2 153 081	08/1985	United Kingdom	—	—		
	BE	2 255 918	11/1992	United Kingdom	—	—		
	BF	2 256 805	12/1992	United Kingdom	—	—		
	BG	WO 92/01815	09/1972	PCT	—	—		
ALL	BH	WO 90/12814	11/1990	PCT	—	—		

EXAMINER

Carol J. Lee

DATE CONSIDERED

6/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATIONForm PTO-1449 (Modified)
(Use several sheets if necessary)ATTY. DOCKET NO.
AERX058CON3SERIAL NO.
To Be AssignedAPPLICANT
Gonda, et al.FILING DATE
HerewithGROUP
To Be Assigned

A.L.P.	BI	WO 90/14468	11/1990	PCT	—	—		
	BJ	WO 91/01868	02/1991	PCT	—	—		
	BK	WO 92/07599	05/1992	PCT	—	—		
	BL	WO 92/09322	06/1992	PCT	—	—		
	BM	WO 92/15353	09/1992	PCT	—	—		
A.L.P.	BN	WO 93/17728	09/1993	PCT	—	—		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A.L.P.	BO	Colthrope, P. et al., (1992), "The pharmacokinetics of pulmonary delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit." <i>Pharmaceutical Research</i> 9:764-8.
	BP	Elliott, R.B. et al., (1987), "Parenteral absorption of insulin from the lung in diabetic children." <i>Aust. Paediatr. J.</i> 23:298-297.
	BQ	Kohler, D., (1990), "Aerosols for systemic treatment." <i>Lung Suppl.</i> :677-84.
	BR	Laube, B.L., et al., (1991), "Deposition, clearance, and effects in the lung." <i>Journal Aerosol Medicine</i> 4:286.
	BS	Laube, B.L., et al., (1994), "Preliminary Study of the Efficacy of insulin aerosol delivered by oral inhalation in diabetic patients." <i>JAMA</i> 269:2106-2109.
	BT	Moses, A.C., et al., (1983), "Insulin administered intranasally as an insulin-bile salt aerosol-effectiveness and reproducibility in normal and diabetic subjects." <i>Diabetes</i> 32:1040-7.
	BU	Newman, S.P., et al., (1981), "Deposition of pressurized aerosols in the human respiratory tract." <i>Thorax</i> . 36:52-55.
	BV	Newman, S.P., et al., (1981), "How Should a pressurized β -adrenergic bronchodilator be inhaled." <i>Eur. J. Respir. Dis.</i> 62:3-21.
	BW	Newman, S.P., et al., (1981) "Deposition of pressurized suspension aerosols inhaled through extension devices." <i>Am. Rev. Respir. Dis.</i> 124:317-320.
	BX	Newman, S.P., et al. (1983) <i>Deposition and Effects of Inhalation Aerosols</i> . Royal Free Hospital. London, ISBN-91-86058-03-07.
A.L.P.	BY	Remington's Pharmaceutical Sciences, A.R. Gennaro, ed., 1985, Mack Publishing Co.

EXAMINER

Carol L. Lau

DATE CONSIDERED

6/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. AERX058CON3	SERIAL NO. To Be Assigned
	APPLICANT Gonda, et al.	
	FILING DATE Herewith	GROUP To Be Assigned

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A.L.L.	BZ	Salzman, R. (1985) "Intranasal aerosolized insulin mixed-meal studies and long-term use in type 1 diabetes." <i>New England Journal of Medicine</i> 213:1078-84.
A.L.L.	CA	Sciarra et al., (1976), "In Vitro Release of Therapeutically Active Ingredients from Polymer Matrixes." <i>Journal of Pharmaceutical Sciences</i> 65(4):1519-1522.
A.L.L.	CB	Wigley, F.M., et al., (1971) "Insulin across respiratory mucosae by aerosol delivery." <i>Diabetes</i> 20:552-556.
A.L.L.	CC	Yoshida, H., et al., (1979) "Absorption of insulin delivered to rabbit trachea using aerosol dosage form." <i>Journal Pharmaceutical Sciences</i> 68:670-1

EXAMINER <i>Carol J. Lunn</i>	DATE CONSIDERED <i>6/21/02</i>
-------------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.